《大行報告》瑞信上調名創優品(MNSO.US)目標價至18美元 評級「跑贏大市」
瑞信發表研究報告,預測名創優品(09896.HK)(MNSO.US)截至去年12月底止第二財季收入將按年下跌11%,達到24.79億元人民幣,經調整淨利潤則預期增長41%至2.9億元人民幣,毛利率進一步改善至36%,經調整淨利潤率則提升至12%。
該行預計,雖然MINISO品牌的國內銷售受疫情影響而較疲軟,但海外銷售表現強勁,目前海外市場已成爲主要的增長動力。門店擴張方面,預期第二財季國內及海外市場的淨開店49家及100家,全年度淨開店150家及250家。
瑞信又指,年初至今國內市場復甦趨勢良好,維持對2023財年第二季盈利預測基本不變,並將2023至2025財年盈利預測分別上調3%、10%及10%,預計門店擴張將加快,銷售亦將復甦,名創優品(MNSO.US)目標價從11美元上調至18美元,重申「增持」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.